N-Substituted amino acid N′-benzylamides: Synthesis, anticonvulsant, and metabolic activities

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 11, 2004, Pages 3079-3096

  Béguin, Cécile ^a   LeTiran, Arnaud ^a   Stables, James P ^b   Voyksner, Robert D ^c   Kohn, Harold ^d  

^a University of Houston   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c LCMS Limited   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Amino acid N benzylamides; Anticonvulsants; Metabolism; Synthesis

Indexed keywords

AMINE; AMINO ACID DERIVATIVE; ANTICONVULSIVE AGENT; DRUG METABOLITE; N BENZYL 2 (2 METHOXYETHYLAMINO) 2 PHENYLACETAMIDE; N BENZYL 2 (2 METHOXYETHYLAMINO) 3 METHOXYPROPIONAMIDE; N BENZYL 2 (2 METHOXYETHYLAMINO)PROPIONAMIDE; N BENZYL 2 (N METHOXY N METHYLAMINO) 2 PHENYLACETAMIDE; N BENZYL 2 (N METHOXY N METHYLAMINO)PROPIONAMIDE; N BENZYL 2 (N METHOXYLAMINO) 2 PHENYLACETAMIDE; N BENZYL 2 (N METHOXYLAMINO)PROPIONAMIDE; N BENZYL 2 [BIS(2 METHOXYETHYL)AMINO] 2 PHENYLACETAMIDE; N BENZYL 2 [BIS(2 METHOXYETHYL)AMINO]PROPIONAMIDE; N BENZYL 2 DIMETHYL D6 AMINO 2 PHENYLACETAMIDE; N BENZYL 2 DIMETHYLAMINO 2 PHENYLACETAMIDE; N BENZYL 2 DIMETHYLAMINO 2 PHENYLACETAMIDE N OXIDE; N BENZYL 2 DIMETHYLAMINO 3 METHOXYPROPIONAMIDE; N BENZYL 2 ETHYLAMINO 2 PHENYLACETAMIDE; N BENZYL 2 ETHYLAMINO 3 METHOXYPROPIONAMIDE; N BENZYL 2 METHOXYAMINO 3 METHOXYPROPIONAMIDE; N BENZYL 2 METHYLAMINO 3 METHOXYPROPIONAMIDE; N BENZYL 2 MORPHOLIN 4 YL 3 METHOXYPROPIONAMIDE; N BENZYL 2 MORPHOLIN 4 YLPROPIONAMIDE; N BENZYL 2 PYRROLIDIN 1 YL 2 PHENYLACETAMIDE; N BENZYL 2 PYRROLIDIN 1 YLPROPIONAMIDE; PENTETRAZOLE; PHENYTOIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC SHOCK; IN VITRO STUDY; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; RAT; SEIZURE; STRUCTURE ACTIVITY RELATION;

AMIDES; AMINO ACIDS; ANIMALS; ANTICONVULSANTS; BENZYL COMPOUNDS; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 18244431460     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.02.043     Document Type: Article

References (43)

1. Cortes S., Liao Z.-K., Watson D., Kohn H. J. Med. Chem. 28:1985;601
2. Conley J.D., Kohn H. J. Med. Chem. 30:1987;567
3. Kohn H., Conley J.D. Chem. Br. 24:1988;231
4. Kohn H., Conley J.D., Leander J.D. Brain Res. 457:1988;371
5. Kohn H., Sawhney K.N., LeGall P., Conley J.D., Robertson D.W., Leander J.D. J. Med. Chem. 33:1990;919
6. Kohn H., Sawhney K.N., LeGall P., Robertson D.W., Leander J.D. J. Med. Chem. 34:1991;2444
7. Kohn H., Sawhney K.N., Bardel P., Robertson D.W., Leander J.D. J. Med. Chem. 36:1993;3350
8. Bardel P., Bolanos A., Kohn H. J. Med. Chem. 37:1994;4567
9. Kohn H., Sawhney K.N., Robertson D.W., Leander J.D. J. Pharm. Sci. 83:1994;689
10. Choi D., Stables J.P., Kohn H. J. Med. Chem. 39:1996;1907
11. Shen M., LeTiran A., Xiao Y., Golbraikh A., Kohn H., Tropsha A. J. Med. Chem. 45:2002;2811
12. LeTiran A., Stables J.P., Kohn H. J. Med. Chem. 45:2002;4762
13. Paruszewski R., Rostafinska-Suchar G., Strupinska M., Jaworski P., Stables J.P. Pharmazie. 3:1996;145
14. Paruszewski R., Rostafinska-Suchar G., Strupinska M., Jaworski P., Winiecka I., Stables J.P. Pharmazie. 51:1996;212
15. Paruszewski R., Rostafinska-Suchar G., Strupinska M., Winiecka I., Stables J.P. Pharmazie. 55:2000;27
16. Paruszewski R., Strupinska M., Stables J.P., Swiader M., Czuczwar S., Kleinrock Z., Turski W. Chem. Pharm. Bull. 49:2001;629
17. Ho B., Venkatarangan P.M., Cruse S.F., Hinko C.N., Andersen P.H., Crider A.M., Adloo A.A., Roane D.S., Stables J.P. Eur. J. Med. Chem. 33:1998;23
18. Andurkar S.V., Stables J.P., Kohn H. Bioorg. Med. Chem. 7:1999;2381
19. Choi D., Stables J.P., Kohn H. Bioorg. Med. Chem. 4:1996;2105
20. Andurkar S.V., Stables J.P., Kohn H. Tetrahedron: Asymmetry. 9:1998;3841
21. Stables J.P., Kupferberg H.J. Avanzini G., Tanganelli P., Avoli M. Molecular and Cellular Targets for Antiepileptic Drugs. 1997;191-198 John Libbey, London
22. White H.S., Woodhead J.H., Franklin M.R. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th ed. 1995;99-110 Raven, New York
23. Dunham M.S., Miya T.A. J. Am. Pharm. Assoc. Sci. Edit. 46:1957;208
24. LeTiran A., Stables J.P., Kohn H. Bioorg. Med. Chem. 9:2001;2693
25. Carter, H. E.; West, D. W. Org. Synth. Coll. Vol. III, 1955; pp 774-775
26. Hoffman R.V., Nayyar N.K., Chen W.T. J. Org. Chem. 58:1993;2355
27. Shah K.J., Trivedi J.J. Indian J. Appl. Chem. 1967;11
28. Brain C.T., Hallett A., Ko S.Y. J. Org. Chem. 62:1997;3808
29. Jong-Man K., Wilson T.E., Norman T.C., Schultz P.G. Tetrahedron Lett. 37:1996;5309
30. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., Swinyard E.A. Epilepsia. 19:1978;409
31. Porter R.J., Cereghino J.J., Gladding G.D., Hessie B.J., Kupferberg H.J., Scoville B., White B.G. Cleveland Clin. Q. 51:1984;293
32. (a) Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E. Epilepsy Res. 43:2001;11
33. (b) Stables, J. P.; Kohn, H. Unpublished results
34. A similar response was observed for 17 when administered to mice (ip) at 46 and 83 mg/kg
35. Stables, J. P. Private communication based on unpublished data performed by the ASP
36. Surh Y.-J., Ahn S.H., Kim K.-C., Park J.-B., Sohn Y.W., Lee S.S. Life Sci. 56:1995;305. and references cited therein
37. Rose J., Castagnoli N. Jr. Med. Res. Rev. 3:1983;73
38. Bickel M.H. Arch. Biochem. Biophys. 148:1972;54
39. Beckett A.H., Triggs E.J. Nature. 211:1966;1415
40. Guengerich F.P., Yun C.H., Macdonald T.L. J. Biol. Chem. 271:1996;27321
41. Kushner S., Cassell R.I., Morton J. II, Williams J.H. J. Org. Chem. 16:1951;1283
42. For comparable procedures for resolving stereoisomers, see the following. Weisman G.R. Morrison J.D. Asymmetric Synthesis - Analytical Methods. Vol. 1:1983;153-171 Academic, New York
43. Parker D., Taylor R.J. Tetrahedron. 43:1987;5431